- Report
- March 2024
- 181 Pages
Global
From €3237EUR$3,374USD£2,799GBP
€3597EUR$3,749USD£3,111GBP
- Report
- February 2024
- 120 Pages
Global
From €4558EUR$4,750USD£3,941GBP
- Report
- February 2021
- 420 Pages
United States
From €2303EUR$2,400USD£1,991GBP
- Report
- November 2022
- 100 Pages
Global
From €5709EUR$5,950USD£4,937GBP
- Report
- February 2020
- 253 Pages
Global
From €5997EUR$6,250USD£5,186GBP
- Report
- March 2019
- 20 Pages
Global
€9595EUR$10,000USD£8,297GBP
- Report
- May 2022
- 83 Pages
Global
From €3358EUR$3,500USD£2,904GBP
- Drug Pipelines
- November 2018
- 70 Pages
Global
From €3358EUR$3,500USD£2,904GBP
- Book
- February 2024
- 592 Pages
Vortioxetine is a medication used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is a serotonin modulator and stimulator (SMS) that works by increasing the levels of serotonin in the brain. Vortioxetine is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2013. It is available in both immediate-release and extended-release formulations.
Vortioxetine is one of several drugs used to treat mental disorders, including antidepressants, antipsychotics, and mood stabilizers. It is generally well-tolerated and has fewer side effects than other drugs in its class. It is also used off-label to treat other conditions, such as obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD).
The market for vortioxetine is growing, as it is becoming increasingly accepted as an effective treatment for mental disorders. It is also becoming more widely available, with many generic versions now available.
Some companies in the vortioxetine market include Lundbeck, Takeda Pharmaceuticals, and Mylan. Show Less Read more